1·A careful assessment for causes of virologic failure is necessary before regimen change and all issues should be addressed to decrease risk of a second treatment failure.
更改治疗前，必须严格仔细评估病毒学失败的原因，把所有可能的不利因素降到最低，避免二线治疗失败。
2·Conclusion it would be helpful to adjust the therapeutic regimen by testing YMDD mutations in patients who receive lamivudine therapy more than 6 months without complete virologic response.
结论对拉米夫定治疗6个月以上而没有达到病毒学完全应答的患者进行YMDD变异检测，有助于及时调整治疗方案。
3·Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.
持续病毒学应答可以降低肝硬化和肝病并发症的发生，降低肝癌(肝细胞性癌)和死亡的发生率。
4·The best indicators of sustained virologic response are low pre-treatment serum HBV DNA titers and elevated alanine aminotransferase (ALT) levels.
持续性病毒学应答的最佳指标是较低的治疗前血清hbv DNA滴度和较高的谷丙转氨酶(ALT)水平。
5·CONCLUSIONS: IFN activates NK cells early after treatment is initiated. Their cytotoxic function, in particular, is strongly induced, which correlates to the virologic response.
结论：IFN在治疗初始就能激活NK细胞，其细胞毒性作用被强烈诱导，这与病毒学应答相关。